Swayed By Industry Opposition To 'Intended Use' Rule, FDA Definitively Delays Implementation

US FDA is considering calls for to drop 'totality of circumstances' test and to clarify that mere knowledge of unapproved...

      

Related Stories

• 340B Hospitals May Be Losing Transparency Debate In Congress
• Korea Revises Rules To Curb Rebate Activities, Improve Ethics
• US FDA's Cancer Review Staff Should All Move To Oncology Center of Excellence, Advocates Say

 

Original Article: Swayed By Industry Opposition To 'Intended Use' Rule, FDA Definitively Delays Implementation

More From BioPortfolio on "Swayed By Industry Opposition To 'Intended Use' Rule, FDA Definitively Delays Implementation"